148 related articles for article (PubMed ID: 37921118)
1. Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports.
Žuljević MF; Mijatović A; Marušić SL; Kudrjavets G; Buljan I; Hren D
J Psychoactive Drugs; 2023 Nov; ():1-13. PubMed ID: 37921118
[TBL] [Abstract][Full Text] [Related]
2. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
3. Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P
J Psychoactive Drugs; 2023; 55(2):170-179. PubMed ID: 35384730
[TBL] [Abstract][Full Text] [Related]
4. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
Kangaslampi S; Hausen A; Rauteenmaa T
J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
[TBL] [Abstract][Full Text] [Related]
5. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
Front Psychol; 2017; 8():1238. PubMed ID: 28790944
[TBL] [Abstract][Full Text] [Related]
6. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
[TBL] [Abstract][Full Text] [Related]
7. Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique.
Mosurinjohn S; Roseman L; Girn M
Front Psychiatry; 2023; 14():1077311. PubMed ID: 37181886
[TBL] [Abstract][Full Text] [Related]
8. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
Sweat NW; Bates LW; Hendricks PS
J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
[No Abstract] [Full Text] [Related]
10. Predicting Responses to Psychedelics: A Prospective Study.
Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
[TBL] [Abstract][Full Text] [Related]
11. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
Roseman L; Nutt DJ; Carhart-Harris RL
Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
[No Abstract] [Full Text] [Related]
12. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.
Ko K; Carter B; Cleare AJ; Rucker JJ
Neuropsychiatr Dis Treat; 2023; 19():2105-2113. PubMed ID: 37818448
[TBL] [Abstract][Full Text] [Related]
14. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
15. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
[TBL] [Abstract][Full Text] [Related]
16. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
Sekula AD; Downey L; Puspanathan P
Front Psychol; 2022; 13():813746. PubMed ID: 35310225
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention.
Hovmand OR; Ebbesen Jensen M; Søgaard Juul T; Korsbak Madsen M; MacDonald Fisher P; Siggaard Stenbæk D
J Psychoactive Drugs; 2024 Jan; ():1-10. PubMed ID: 38225795
[TBL] [Abstract][Full Text] [Related]
18. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
[TBL] [Abstract][Full Text] [Related]
19. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
20. Psilocybin occasioned mystical-type experiences.
James E; Robertshaw TL; Hoskins M; Sessa B
Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
